<DOC>
	<DOC>NCT00941486</DOC>
	<brief_summary>The objective of this study is to evaluate the efficacy of FST-100 (0.1% dexamethasone) Ophthalmic Suspension in the treatment of suspected acute adenoviral conjunctivitis.</brief_summary>
	<brief_title>FST-100 Ophthalmic Suspension in Acute Adenoviral Conjunctivitis</brief_title>
	<detailed_description />
	<mesh_term>Conjunctivitis</mesh_term>
	<mesh_term>Conjunctivitis, Inclusion</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Conjunctivitis within seven (7) days of initial ocular symptoms of redness and/or discharge. Clinical suspicion of adenoviral etiology. At least three (3) years of age. Subjects or their guardians capable of understanding the purpose and risks of the study, and able to give informed consent. Conjunctivitis diagnosis defined as presence of the two cardinal signs of acute conjunctivitis: 1. conjunctival injection/inflammation, and 2. conjunctival discharge/exudates. Conjunctivitis longer than 7 days after initial ocular symptoms. Corneal ulcer, endophthalmitis, or any other confounding infection of the eye. Patients taking ocular antiinflammatory medications on a chronic basis. Active herpes ocular infection. Known or suspected pregnancy. Known allergy to PVPI. Known allergy to dexamethasone. Patients with a history of elevation in intraocular pressure as a result of steroid use ("steroid responders".</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
</DOC>